The period between regulatory submission and FDA approval is probably one of the most underutilised windows in life sciences. Most teams wait. But here is what the smartest medical affairs and commercial teams are doing during that window: they are identifying, engaging, and building trust with the clinicians who will drive adoption of their therapy at launch. ... Read this blog

In biotech companies, the success of a new therapy depends not only on clinical efficacy but also on how effectively you engage key opinion leaders (KOLs). Ultimately, they are the ones who will adopt it in clinical practice and champion it on podiums and among peers. ... Read this blog